Clinical-stage biopharmaceutical company engaged in the development and commercialization of drugs to treat important ophthalmic disorders. Our lead drug candidate, preservative-free Nyxol® Eye Drops, is being developed for multiple front-of-the-eye indications, including night vision disturbances, reversal of pharmacologically-induced mydriasis, and presbyopia.
Ocuphire
